Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

The Trust Test

- PMLiVE

FDA restricts use of certain antibody treatments for COVID-19

The restrictions reflect recent data that shows these antibodies are not effective against the Omicron variant

https://youtu.be/_T3WV2TR0U8

Let’s explore new frontiers

Oxford PharmaGenesis

- PMLiVE

FDA grants priority review for Roche’s Evrysdi for spinal muscular atrophy in babies

The review of Evrysdi has been developed for pre-symptomatic babies under two months old with spinal muscular atrophy

- PMLiVE

Ipsen’s Sohonos approved by Health Canada

The drug is the first approved treatment for individuals with fibrodysplasia ossificans progressiva

- PMLiVE

Personalised medicine: driving a need for greater diversity in clinical trials

Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today.

Innovative Trials

Lucid Group Welcomes a New Cohort of Graduates into its Futures Academy

We are excited to welcome this year’s cohort of graduates into our Lucid Futures Academy, which is now into its sixth year after being launched in Oct 2017.The Futures Academy...

Lucid Group Communications Limited

- PMLiVE

Gilead’s Veklury receives FDA approval for non-hospitalised high-risk patients to treat COVID-19

The FDA also issued an EUA for the treatment to include non-hospitalised paediatric patients 12 years and under who are at high risk of disease progression

- PMLiVE

SMC approves Parkinson’s disease treatment Ongentys

The once-daily additional oral treatment for patients living with Parkinson’s disease is now accepted for use within NHS Scotland

- PMLiVE

Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events

With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay

- PMLiVE

Home or away: where next for pharmaceutical symposia?

By Nick Burgoyne

- PMLiVE

PM announces plans to lift England’s COVID-19 restrictions

Following the announcement, England is set to remove its ‘Plan B’ COVID-19 restrictions over the next week

- PMLiVE

Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment

The study evaluated the combination of Lenvima plus Keytruda versus chemotherapy for patients diagnosed with advanced, metastatic, or recurrent endometrial carcinoma

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links